Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

Researches have helped in detecting the disease in early stages and drugs are now being made available for an effective and ...

On World Alzheimer’s Day, we examine how a timely diagnosis can prepare someone with early dementia, and the pros and cons of ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

Bre Teamer chats with Dr. Alex Zayid of Icon Anti-Aging about recent developments and research that supports using ...

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...